Physician profile
Joseph Pascal
NPI 1154321750
$1,121.89
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $121 · 2021: $37.41 · 2022: $17.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $309.05 | 2019-2020 | |
| Pfizer INC. | $279.23 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.94 | 2019 | |
| Karl Storz Endoscopy-America | $73.44 | 2019 | |
| Photocure INC | $47.21 | 2019 | |
| Janssen Biotech, INC. | $43.05 | 2019-2020 | |
| Axonics, INC. | $37.41 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $34.61 | 2019 | |
| Olympus America INC. | $17.49 | 2022 | |
| Medtronic USA, INC. | $16.70 | 2019 | |
| Blue Earth Diagnostics | $13.52 | 2019 | |
| Travere Therapeutics, INC. | $10.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pascal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.